Urgences
Traitements
Infos médecins
Centre de recherche
Faire un don
Liens |
|
 |
|
|
|
| Home < Centre de recherche < Etudes cliniques |     |
|
Info.onco@chuv.ch | ||||||||||||
Etudes cliniques
Les études cliniques auxquelles le Cepo prend part touchent aux différentes pathologies oncologiques:
Pour toute information complémentaire, merci de vous adresser directement au principal investigateur à Lausanne.
(Les documents ci-dessous sont au format pdf et varient entre 36k et 123k)
|
Indication |
Titre |
Phase |
Nom |
| Colo-Rectal, métastatique maintenance | Bevacizumab maintenance versus no maintenance after stop of first-line chemotherapy in patients with metastatic colorectal cancer. A randomized multicenter phase III non-inferiority trial. | Phase III | SAKK 41/06 |
| Carcinome hépatocellulaire, stade B et C | Sorafenib alone or in combination with everolimus in patients with unresectable hepatocellular carcinoma. A randomized multicenter phase II trial. | Phase II | SAKK 77/08 |
| Carcinome hépatocellulaire, stade B | A phase I open label/phase II randomized, double-blind,multicenter trial investigating the combination of everolimus and TransArterial ChemoEmbolisation (TACE) with doxorubicin in patients with hepatocellular carcinoma. | Phase I/II | SAKK 77/09 |
| œsophage et jonction gastroesophagienne sup., localement avancé (stade II à IVa) |
Multimodal therapy with and without cetuximab in patients with locally advanced esophageal carcinoma. An open-label phase III trial. |
Phase III | SAKK 75/08 |
Tumeurs gynécologiques / sénologiques
|
Indication |
Titre |
Phase |
Nom |
| Sein néoadjuvant, localement avancé, inflammatoire, grosse tumeur opérable | A phase I-II study of Lapatinib and Docetaxel as neoadjuvant treatment for HER-2 positive locally advanced/inflammatory or large operable breast cancer | Phase I-II | LAPATAX (EORTC 10054) |
| Sein adjuvant (post-ménopausée/ récepteurs hormonaux +) | A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone receptor positive, node positive early stage breast cancer | Phase III | SOLE (BIG 1-07/ IBCSG 35-07) |
| Sein adjuvant, Carcinome canalaire in situ | An international multi-center study of tamoxifen versus anastrozole in postmenopausal women with Ductal Carcinoma in situ (DCIS) | Phase III | IBIS-II (IBCSG 31/03) |
| Sein Radiothérapie ADJUVANTE | SUPREMO, an MRC sponsored phase III randomised trial to assess the role of adjuvant chest wall irradiation in ‘intermediate risk’ operable breast cancer following mastectomy. (Selective Use of Postoperative Radiotherapy AftEr MastectOmy) | Phase III | SUPREMO (BIG 2-04) |
| Sein Métastatique, 1ère-2ème ligne | Randomized phase III trial of Herceptin® followed by chemotherapy plus Herceptin® versus the combination of Herceptin® and chemotherapy as palliative treatment in patients with HER2-overexpressing advanced/metastatic breast cancer | Phase III | SAKK 22/99 |
| Sein Métastatique | Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative metastatic or locally recurrent breast cancer. A multicenter, randomized phase III trial. | Phase III | SAKK 24/09 |
| Sein Métastatique | Fulvestrant with or without AZD6244, a mitogenactivated protein kinase kinase (MEK) 1/2 inhibitor, in advanced stage breast cancer progressing after aromatase inhibitor: a randomized placebo-controlled double-blind phase II trial. | Phase II | SAKK 21/08 |
|
Indication |
Titre |
Phase |
Nom |
| Leucémie promyélocytaire aiguë | A randomized phase III trial assessing the role of arsenic trioxide and/or ATRA during consolidation course in newly diagnosed acute promyelocytic leukemia (APL) | Phase III | APL 2006 |
| Leucémie Lymphoblastique aigüe (ALL), < 60 ans | Protocole multicentrique de traitement des Leucémies aigües Lymphoblastiques (LAL) de l’adulte jeune (18-59 ans) | Phase III | GRAALL 2005 |
| Leucémie myéloïde aiguë | Randomized study with a run-in feasibility phase to assess the added value of Clofarabine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS = 1.5) | Phase III | SAKK 30/09 HOVON 102 |
...
...
|
Indication |
Titre |
Phase |
Nom |
| Lymphomes diffus à grandes cellules B, patients âgés de 60-80 ans, après réponse par chimiothérapie initiale | Double blind randomized phase III study of lenalidomide (REVLIMID®) maintenance versus placebo in responding elderly patients with DLBCL and treated with R-CHOP in first line | Phase III | REMARC |
| Lymphomes diffus à grandes cellules B, en rechute/ réfractaire | Ibritumomab tiuxetan (Zevalin) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. | Phase I | SAKK 37/05 |
| Lymphome agressif à cellules B récidivant ou réfractaire | Rituximab, bendamustine and lenalidomide in patients with relapsed or refractory aggressive B-cell lymphoma not eligible for high dose chemotherapy. | A phase I/II trial. | SAKK 38/08 |
Hématologie / Myélomes multiples
|
Indication |
Titre |
Phase |
Nom |
| Cutané, stade III/IV, patients HLA-A2+, tumeur Melan-A+ et positivité pour MAGE-A10 &/ou NY-ESO &/ou LAGE-1 | Immunothérapie de patients HLA-A2 positifs atteints de mélanome cutané de stade III/IV à l'aide des peptides antigéniques Melan-A analogue, NY-ESO-1b analogue et MAGE-A10 et de l’adjuvant Montanide | Phase I | LUD 01-003 |
| Mélanome, stade II à IV, HLA A2+, Melan A+ | Vaccination of melanoma patients (stage II-IV) with ImmuFact IMP321, tumor antigenic peptides and Montanide | Phase I/IIa | sLAG-3 |
| Mélanome métastatique, stade IIIc non résécable ou stade IV, mutation du gène B-RAF | An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma | Phase IIIb | MO25515 |
| Mélanome métastatique avec métastases cérébrales symptomatiques, mutation du gène B-RAF | An open-label, pilot study of RO5185426 in previously treated metastatic melanoma patients with brain metastases | Phase II | MO25653 |
|
Indication |
Titre |
Phase |
Nom |
| Tumeur solide, localement avancée ou métastatique |
An Open-Label, Safety, Pharmacokinetic and Pharmacodynamic, Dose escalation Phase Ib Study of Pazopanib in combination with Epirubicin or Doxorubicin in Subjects with Advanced Solid Tumors |
Ib | VEG109603-Pazopanib |
| Néoplasies hématologiques avancées | Advanced hematologic malignancies (multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, malignant lymphoma), Phase I trial of nelfinavir and bortezomib in advanced hematologic malignancies | Phase I | SAKK 65/08 |
|
Indication |
Titre |
Phase |
Nom |
| NSCLC, Stade IIIA | Preoperative chemoradiotherapy vs. chemotherapy alone in non-small cell lung cancer (NSCLC) patients with mediastinal lymph node metastases (stage IIIA, N2): A randomized prospective phase III trial | Phase III | SAKK 16/00 |
| NSCLC, avancé (stade IIIB) mais opérable | Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial. | Phase II | SAKK 16/08 |
| NSCLC, cancers non-épidermoïdes avancés (stade IV) | Bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. A multicenter phase II trial including biopsy at progression (BIO-PRO trial). | Phase II | SAKK 19/09 |
| Mésothéliome, 1er diagnostic | Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy | Phase II | SAKK 17/04 |
|
Indication |
Titre |
Phase |
Nom |
| Sarcome, GIST, 1ère ligne | Dasatinib first-line treatment in gastrointestinal stromal tumors | Phase II | SAKK 56/07 |
| Sarcome, GIST, metastatic or locally advanced, inoperable disease. | Radiation therapy as a palliative treatment of GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective phase II study | Phase II | GIST-RT-2007 |
|
Indication |
Titre |
Phase |
Nom |
| Des gliomes anaplasiques, OMS Grade III: Astrocytome anaplasique, Oligoastrocytome anaplasique et Oligodendrogliome anaplasique sans perte de translocation chromosomique de 1p/19q | Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. | Phase III | EORTC 26053-22054 CATNON |
| Glioblastome, adjuvant | A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM | Phase III | Novocure – EF-14 |
| Glioblastome, adjuvant | Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II study. | Phase II | EORTC 26082-22081 |
Tumeurs du système uro-génital
Dernière modification le
21.09.2011